www.innocyto.com.cn

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

Anti-Human ASGR1 Antibody

Catalog Number:	117401, 117402
Size:	25 µg, 100 µg
Target Name:	ASGR1, ASGPR1
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	ICASG1AB
Application:	Flow Cytometry, ICC
Reactivity:	Human
Format:	Purified
Isotype:	Rabbit IgG
Antibody Type:	Monoclonal
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Protein Concentration:	0.5 mg/mL
Storage & Handling:	The antibody solution should be stored between 2°C and 8°C
Recommended Usage:	For flow cytometric staining, it is recommended to use less than 0.2 µg of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application
Isotype Control:	303301

BACKGROUND INFORMATION

Human ASGR1 (asialoglycoprotein receptor 1) is a type II transmembrane lectin primarily expressed on the surface of hepatocytes in the liver. It forms the major subunit of the asialoglycoprotein receptor (ASGPR), a receptor complex responsible for the rapid clearance of circulating glycoproteins that have lost their terminal sialic acid residues. By recognizing exposed galactose or N-acetylgalactosamine (GalNAc) residues, ASGR1 mediates receptor-dependent endocytosis and lysosomal degradation of these glycoproteins, thereby maintaining serum glycoprotein homeostasis and contributing to liver-specific clearance of endogenous and exogenous molecules.


Structurally, ASGR1 is a calcium-dependent C-type lectin receptor composed of a short cytoplasmic tail, a single transmembrane domain, a stalk region, and a C-terminal carbohydrate recognition domain (CRD). The receptor typically forms hetero-oligomeric complexes with ASGR2, which enhance ligand binding and internalization efficiency. Its principal ligands include desialylated glycoproteins bearing terminal galactose or GalNAc residues, and ligand binding requires calcium ions for high-affinity recognition.

ASGR1 has been implicated in lipid metabolism and cardiovascular disease. Naturally occurring loss-of-function variants in ASGR1 are associated with reduced levels of non-high-density lipoprotein cholesterol and a lower risk of coronary artery disease, suggesting that the receptor influences cholesterol homeostasis in addition to glycoprotein clearance. Altered ASGR1 expression

has also been investigated in liver diseases, although its precise contribution to hepatic pathology remains under active study.

ASGR1 has become an important therapeutic target because its highly selective expression on hepatocytes enables liver-specific drug delivery. Triantennary GalNAc conjugates bind ASGR1 with high affinity and efficiently deliver small interfering RNAs, antisense oligonucleotides, and other nucleic acid therapeutics into hepatocytes. This targeting strategy has substantially improved the efficacy and safety of numerous liver-directed therapies and represents a major advance in precision medicine for metabolic, genetic, and infectious liver diseases.

PRODUCT DATA



HepG2 Cells were stained with Purified Anti-Human ASGR1 clone ICASG1AB (color-filled histogram) or an isotype control (gray histogram), followed by PE Anti-Rabbit IgG.

This product is supplied subject to the terms and conditions at www.innocyto.com.cn/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.